Marcin Miszczyk
Overview
Explore the profile of Marcin Miszczyk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
176
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kardoust Parizi M, Singla N, Matsukawa A, Tsuboi I, Mancon S, Miszczyk M, et al.
BJU Int
. 2025 Mar;
PMID: 40070078
Objectives: To evaluate the results of randomised controlled trials (RCTs) regarding the efficacy of human papillomavirus (HPV) vaccination in preventing male genital-related diseases. Methods: A systematic search of English language...
2.
Tsuboi I, Matsukawa A, Kardoust Parizi M, Schulz R, Mancon S, Fazekas T, et al.
Clin Genitourin Cancer
. 2025 Feb;
23(2):102306.
PMID: 39952876
Despite currently used intravesical therapies in non-muscle-invasive bladder cancer (NMIBC), the rate of intravesical recurrence remains very high. We aimed to evaluate the effectiveness of adding nonintravesical interventions to standard...
3.
Matsukawa A, Yanagisawa T, Miszczyk M, Kimura T, Shariat S
Eur Urol Focus
. 2025 Feb;
PMID: 39922752
No abstract available.
4.
Matsukawa A, Litterio G, Cormio A, Miszczyk M, Kardoust Parizi M, Fazekas T, et al.
Cancers (Basel)
. 2025 Jan;
17(2).
PMID: 39857987
: The addition of androgen receptor pathway inhibitors (ARPIs) to androgen deprivation therapy (ADT), with or without docetaxel (Doc), is currently recommended for metastatic, hormone-sensitive prostate cancer (mHSPC). Recently, the...
5.
Matsukawa A, Yanagisawa T, Miszczyk M, Kardoust Parizi M, Fazekas T, Tsuboi I, et al.
Eur Urol Focus
. 2025 Jan;
PMID: 39848859
Background And Objective: There is an established association between secondary bladder cancers (SBCs) and radiotherapy (RT) for prostate cancer (PC), which remains a significant concern. Our aim was to update...
6.
Soeterik T, Heetman J, Hermsen R, Wever L, Lavalaye J, Vinken M, et al.
Eur Urol Oncol
. 2024 Nov;
PMID: 39613565
Background And Objective: The role of prostate-specific membrane antigen (PSMA)-based positron emission tomography (PET)/computed tomography (CT) in addition to magnetic resonance imaging (MRI) for local staging of prostate cancer (PC)...
7.
Matsukawa A, Yanagisawa T, Miszczyk M, Kardoust Parizi M, Fazekas T, Tsuboi I, et al.
Eur Urol Focus
. 2024 Nov;
PMID: 39578213
Background And Objective: Radical cystectomy (RC) is the standard treatment for muscle-invasive bladder cancer (MIBC). It is highly invasive and associated with perioperative risks, while bladder-preserving trimodality therapy (TMT) offers...
8.
Matsukawa A, Yanagisawa T, Rajwa P, Fazekas T, Miszczyk M, Tsuboi I, et al.
Clin Genitourin Cancer
. 2024 Nov;
23(1):102251.
PMID: 39571519
Background: Androgen-receptor signaling inhibitors (ARSIs) significantly improve survival in systemic therapy for advanced/metastatic prostate cancer (PCa) patients; however possible central nervous system (CNS) toxicity is an unaddressed concern. We aimed...
9.
Tsuboi I, Matsukawa A, Kardoust Parizi M, Miszczyk M, Fazekas T, Schulz R, et al.
Clin Genitourin Cancer
. 2024 Nov;
22(6):102237.
PMID: 39546952
Although immune checkpoint inhibitors (ICI) and/or tyrosine kinase inhibitors (TKI) are the standard treatment of advanced unresectable or metastatic renal cell carcinoma (RCC), the impact of concomitant medications remains unclear....
10.
Miszczyk M, Malec-Milewska M, Suleja A, Dolla L, Wydmanski J, Kocot-Kepska M, et al.
Contemp Oncol (Pozn)
. 2024 Nov;
28(3):242-244.
PMID: 39512530
Introduction: Celiac plexus radioablation (CPR) is an emerging non-invasive interventional treatment for severe pain associated with cancer-related damage to the celiac plexus. Due to its complex aetiology, such pain often...